Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients

• Status: Completed
• Trial end date: 2005-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The incidence of efficacy failure at 12 months between two regimens.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Everolimus; Sirolimus

Criteria

Inclusion Criteria

• Age: 13 years or older, 40 kgs or more

• End-stage renal disease

• African-American/Black transplant recipient and/or repeat renal transplant recipient who lost a previous allograft

Exclusion Criteria

• Evidence of active infection

• Evidence abnormal chest x-ray

• Patients with HIV.